A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
In the double-masked, randomized, multi-center, active-controlled parallel study, patients
will be randomized to receive either a fixed dose combination of AR-12286 and travoprost,
AR-12286, or travoprost. The hypothesis is that there is no difference between each treatment
arm.